Divalproex Sodium Tablet, Delayed Release
Product Images NDC 60687-868

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 60687-868). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

125 mg Divalproex Sodium Dr Tablet Blister.jpg (125 mg Divalproex Sodium Dr Tablet Blister)

Multiple identical labels for Divalproex Sodium Delayed Release Tablets, USP 125 mg. Each label shows the product name, strength, tablet dosage form, a placeholder for lot number and expiry date, a barcode, and the labeler American Health Packaging, Columbus, OH 43227.*

FDA Label Image

125 mg Divalproex Sodium Dr Tablets Carton.jpg (125 mg Divalproex Sodium Dr Tablets Carton)

Divalproex Sodium 125 mg delayed release tablets, USP, with valproic acid activity, in a package containing 30 tablets (3 x 10) for oral use. The label includes dosage and storage instructions, pharmacy dispensing information, and identifies American Health Packaging as the distributor.*

FDA Label Image

250 mg Divalproex Sodium Dr Tablet Blister.jpg (250 mg Divalproex Sodium Dr Tablet Blister)

Divalproex Sodium 250 mg delayed release tablet labels from American Health Packaging are shown. Each label includes the product name, dosage strength, tablet form, lot number placeholder, expiration date placeholder, and barcode. The tablets are intended for oral use.*

FDA Label Image

250 mg Divalproex Sodium Dr Tablets Carton.jpg (250 mg Divalproex Sodium Dr Tablets Carton)

Label for Divalproex Sodium 250 mg delayed release oral tablets. The label indicates a package size of 100 tablets (10 x 10) and highlights valproic acid activity. It includes instructions for pharmacists to dispense with a medication guide, storage conditions, and a QR code for current medication guide and prescribing information. The product is distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

500 mg Divalproex Sodium Dr Tablet Blister.jpg (500 mg Divalproex Sodium Dr Tablet Blister)

Label for Divalproex Sodium 500 mg delayed release tablets for oral use. The label displays the drug name, strength, dosage form, barcode, expiration date, and lot number fields. It is labeled by American Health Packaging, Columbus, Ohio.*

FDA Label Image

500 mg Divalproex Sodium Dr Tablets Carton.jpg (500 mg Divalproex Sodium Dr Tablets Carton)

Divalproex Sodium Delayed Release Tablets, USP, 500 mg, oral dosage form. The label shows a package containing 90 tablets (9 bottles of 10 tablets each) with Valproic Acid activity. Distributed by American Health Packaging with storage instructions and medication guide note for pharmacists included.*

FDA Label Image

Ahp85721

Divalproex Sodium 125 mg delayed-release tablet, oral administration. The tablet is oblong and light orange with the imprint UL125 on one side. Labeled by American Health Packaging.*

FDA Label Image

Ahp86801

Divalproex Sodium 250 mg delayed-release oral tablet, pink, oval-shaped with imprint 'UL250' on one side. The labeler is American Health Packaging. The image shows both the imprinted and non-imprinted sides of the tablet.*

FDA Label Image

Ahp87961

Divalproex Sodium 500 mg delayed-release oral tablet, oblong and pink in color, imprinted with 'UL 500'. Manufactured by American Health Packaging.*

FDA Label Image

Image (D405e38e 5f4d 4977 B36b Fca8c23cf294 01)

Chemical structure diagram of Divalproex Sodium, showing its molecular composition with sodium ion and associated carbon chains.*

FDA Label Image

Image (D405e38e 5f4d 4977 B36b Fca8c23cf294 02)

A bar chart comparing the percentage values between placebo (PBO) and divalproex sodium (DVPX) in two studies labeled Study 1 and Study 2. Each study shows higher percentages for DVPX compared to PBO, with Study 1 at 26% vs 60% and Study 2 at 29% vs 58%. The y-axis represents percentage values from 0% to 70%.*

FDA Label Image

Image (D405e38e 5f4d 4977 B36b Fca8c23cf294 03)

A line graph comparing the percentage reduction in CPS Rate between Divalproex Sodium and placebo across different patient percentages. The vertical axis shows percentage change from worsening to improvement, while the horizontal axis represents the percentage of patients from 100 to 0. The solid line represents Divalproex Sodium, and the dashed line represents placebo.*

FDA Label Image

Image (D405e38e 5f4d 4977 B36b Fca8c23cf294 04)

A line graph showing the percentage reduction in CPS rate versus the percentage of patients, comparing high dose (solid line) and low dose (dashed line) treatments. The vertical axis ranges from -100% to 100% indicating worsening and improvement, while the horizontal axis represents the percentage of patients from 0 to 100.*

FDA Label Image

Image (D405e38e 5f4d 4977 B36b Fca8c23cf294 05)

A bar chart comparing results between placebo and Divalproex Sodium groups in two studies labeled as Study 1 and Study 2. The vertical axis represents a numerical scale from 0 to 6. The chart visually displays differences in measured outcomes for placebo versus Divalproex Sodium in each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.